HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2473 Talquetamab (Anti-GPRC5D) Talquetamab (Anti-GPRC5D) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab exhibits antitumor activity. MW: 145.5 KD. Aug 10 2023
A2474 Petosemtamab (Anti-GPR49 / LGR5) Petosemtamab (Anti-GPR49 / LGR5) is an monoclonal antibody that targets GPR49/LGR5. It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD. Aug 10 2023
A2475 Glembatumumab (Anti-GPNMB) Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. MW: 145.5 KD. Aug 10 2023
A2476 Codrituzumab (Anti-GPC3 / Glypican-3) Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD. Aug 10 2023
A2477 Anti-GPA33 Anti-GPA33 (KRN330) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities. MW: 145.5 KD. Aug 10 2023
A2478 Glenzocimab (Anti-GP6 / Glycoprotein-6) Glenzocimab (Anti-GP6 / Glycoprotein-6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. MW: 145.5 KD. Aug 10 2023
A2479 Racotumomab (Anti-GM3) Racotumomab (Anti-GM3) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer. MW: 145.5 KD. Aug 10 2023
A2480 Anti-GFRAL Anti-GFRAL (NGM120) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL activity which prevents binding of growth differentiation factor 15 (GDF15; MIC-1) to its receptor GFRAL and prevents GDF15/GFRAL-mediated signaling. MW: 145.5 KD. Aug 10 2023
A2481 Nadecnemab (Anti-GFRA3) Nadecnemab (Anti-GFRA3) is an IgG4κ antibody targeting GFRA3 (glial cell derived neurotrophic factor family receptor alpha 3). Nadecnemab can be used for research of osteoarthritis of the knee/pain. MW: 145.5 KD. Aug 10 2023
A2482 Apitegromab (Anti-GDF8 / Myostatin) Apitegromab (Anti-GDF8 / Myostatin) is a fully human monoclonal antibody that binds to human promyostatin and latent myostatin with a high degree of specificity, without binding to mature myostatin and other closely related growth factors. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. MW: 145.5 KD. Aug 10 2023
A2483 Ponsegromab (Anti-GDF15 / MIC-1) Ponsegromab (Anti-GDF15 / MIC-1) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. MW: 145.5 KD. Aug 10 2023
A2484 Ecromeximab (Anti-GD3) Ecromeximab (Anti-GD3) is a human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity that targets ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. It binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. MW: 145.5 KD. Aug 10 2023
A2485 Dinutuximab (Anti-GD2) Dinutuximab (Anti-GD2) is a chimeric mouse/human monoclonal antibody that targets ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. It has potential antineoplastic activity. MW: 145.5 KD. Aug 10 2023
A2486 Naxitamab (Anti-GD2) Naxitamab (Anti-GD2) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. MW: 145.5 KD. Aug 10 2023
A2487 Volagidemab (Anti-GCGR) Volagidemab (Anti-GCGR) is an antagonistic monoclonal antibody (mAb) that targets glucagon receptor (GCGR). Volagidemab can be used in the research of type 1 diabetes (T1D). MW: 145.5 KD. Aug 10 2023
A2488 Tabituximab (Anti-FZD10) Tabituximab (Anti-FZD10) is a humanized monoclonal antibody that targets frizzled class receptor 10 (FZD10). MW: 145.5 KD. Aug 10 2023
A2489 Vantictumab (Anti-FZD) Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD. Aug 10 2023
A2490 Anti-Fucosyl GM1 Anti-Fucosyl GM1 is a antibody that recognizes and targets the fucosyl form of ganglioside GM1. MW: 145.5 KD. Aug 10 2023
A2491 Mirvetuximab (Anti-FOLR1) Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD Aug 10 2023
A2492 Farletuzumab (Anti-FOLR1) Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD Aug 10 2023